3 results about "Secondary hypoparathyroidism" patented technology

This invention relates to the field of pharmaceutical biotechnology, providing the application of aminoquinoline compounds (such as hydroxychloroquine and chloroquine) in the preparation of drugs for treating hyperparathyroidism. These compounds restore the expression of calcium-sensitive receptors (CaSRs) on the cell membrane surface by inhibiting the lysosomal degradation pathway of CaSRs in parathyroid cells. Experiments have confirmed that 4-aminoquinoline compounds, used alone or in combination with calcimimetics (such as cinacalcet), significantly reduce serum PTH and calcium levels in a model of refractory secondary hyperparathyroidism (SHPT) and inhibit glandular hyperplasia. In particular, the combination therapy regimen exhibits a significant synergistic effect, effectively reversing calcimimetics resistance. This invention is the first to discover a novel use for the antimalarial / antirheumatic drug hydroxychloroquine in the treatment of hyperparathyroidism, realizing a new use for an existing drug; and providing a safe and effective new drug treatment strategy for clinically refractory SHPT.

The invention belongs to the technical field of chemical raw material medicines, and particularly relates to an aryl alkyl amine compound as well as a preparation method and application thereof. The structure of the aryl alkyl amine compound is shown as a formula I. Experiments prove that the allosteric agonist effect of the compound provided by the invention on a calcium-sensitive receptor is superior to or equivalent to that of Evocalpet, and the aryl alkyl amine compound has potential in preparation of drugs for treating secondary hyperparathyroidism. Formula I

Disclosed are methods of preventing or reducing loss of kidney function in a chronic kidney disease (CKD) patient having secondary hyperparathyroidism (SHPT).